Considering everything it takes to scale up gene therapy — the platforms, the media, the surfaces, the vessels, the equipment — developing viral vector production processes comes with many challenges.
It's no surprise, then, that labs sometimes miss a few things when scaling their gene therapeutics up or out, and those oversights can set projects back. These are common pitfalls — but most researchers don't realize that they're problematic until it's far too late.
John Yoshi Shyu, Ph.D., who oversees field and internal application scientists at Corning Life Sciences, knows firsthand how one small issue with bioprocess applications can create a wide gap between outcomes and expectations in viral vector production. Here, he identifies four essential things to know about scaling gene therapy processes.